CN-121971413-A - Application of farnesol in preparation of medicine for promoting rapid hemostasis under core hyperthermia condition

Abstract

The invention belongs to the technical field of medicines and disease treatment, and particularly relates to application of farnesol in preparation of medicines for promoting rapid hemostasis under the condition of core hyperthermia. The farnesol realizes the function of actively enhancing physiological hemostasis under the core temperature loss condition by targeted regulation of the neutrophil extracellular trap pathway. The research result of the invention shows that the addition of farnesol into the core hyperthermia blood can promote the release of neutrophil NETs, and increase the blood clot density through the DNA skeleton of NETs, thereby accelerating the blood coagulation under the core hyperthermia condition. The invention provides a hemostasis strategy that does not rely on or largely bypass temperature sensitive exogenous thrombin and other coagulation factors, thereby maintaining efficient and rapid hemostasis in low temperature environments.

Inventors

• Gu Junting
• NIU LINA
• DONG YAN
• WANG YUZHU
• Dang Gaopeng
• JI YINGBO
• XU HAORAN

Assignees

• 中国人民解放军空军军医大学

Dates

Publication Date

20260505

Application Date

20260202

Claims (8)

1. 1. The application of the farnesol in preparing the medicine for promoting the rapid hemostasis under the core hyperthermia condition is characterized in that the farnesol realizes the function of actively enhancing the physiological hemostasis under the core hyperthermia condition by targeted regulation of a neutrophil extracellular trap path; the structure of the farnesol is as follows: 。
2. 2. use according to claim 1. The preparation method is characterized in that the drug takes the farnesol as an active ingredient and is assisted with a pharmaceutically acceptable carrier.
3. 3. The use according to claim 2, wherein the carrier is a random copolymer of 2-phenoxyethyl acrylate, butyl acrylate and acrylic acid; wherein the molar ratio of the acrylic acid-2-phenoxyethyl ester, the butyl acrylate and the acrylic acid is 5-7:2-4:1.
4. 4. The use according to claim 2, wherein the farnesol comprises 0.06% -0.1% of the total mass of the medicament.
5. 5. Use according to claim 2, characterized in that the medicament is used in combination with physical rewarming measures or other hemostatic medicaments.
6. 6. The use according to claim 2, wherein the core hypothermia condition is a body temperature of 35 ℃ or less.
7. 7. The use according to claim 6, wherein the core hyperthermia condition is caused by traumatic blood loss, environmental exposure and/or surgical anesthesia induction.
8. 8. The use according to claim 1, wherein the rapid hemostasis means that a bleeding volume reduction of more than 50% is achieved within 5 minutes after administration.

Description

Application of farnesol in preparation of medicine for promoting rapid hemostasis under core hyperthermia condition Technical Field The invention belongs to the technical field of medicines and disease treatment, and particularly relates to application of farnesol in preparation of medicines for promoting rapid hemostasis under the condition of core hyperthermia. Background Major bleeding caused by severe wounds is one of the main causes of death in extreme environments such as battlefields, traffic accidents, natural disasters, and the like. In these scenarios, the wounded, in addition to suffering physical trauma, is often accompanied by loss of core body temperature, i.e., core hypothermia. The core temperature loss can cause a series of complex physiological and pathological changes, seriously weakens the coagulation function of the organism, forms malignant circulation of 'lethal triple sign' (hypothermia, acidosis and coagulation dysfunction), and leads the efficacy of the traditional hemostasis means to be drastically reduced. At present, aiming at hemostasis in a core temperature losing state, the existing hemostasis technology mainly comprises a physical mechanical material, a bioactive preparation and a rewarming strategy. However, in the core temperature-losing state, the activity of body thrombin is reduced, the platelet function is inhibited, so that physical materials can only be blocked passively and active coagulation cannot be activated, the activity of biological agents is obviously reduced, the cost is high, the thrombus risk is high, the rewarming measures are slow to take effect, and the rapid hemostatic requirement in a gold rescue window is difficult to meet. Existing studies have revealed that Neutrophil Extracellular Traps (NETs) can provide a stable scaffold for thrombus by capturing platelets and erythrocytes, but current focus is mostly on their negative effects in pathological thrombus, and their potential and application to actively enhance physiological hemostasis under core hyperthermia conditions have not been explored. Disclosure of Invention In order to explore the potential and application of Neutrophil Extracellular Traps (NETs) in actively enhancing physiological hemostasis under the core hyperthermia condition, a novel treatment strategy capable of enhancing the self hemostasis function of an organism by targeting and regulating NETs without depending on the supplement of traditional blood coagulation factors or animal physical blocking in the core hyperthermia environment so as to realize rapid, effective and safe hemostasis is developed. In order to achieve the above purpose, the present invention adopts the following technical scheme. The invention provides application of farnesol in preparing a medicament for promoting rapid hemostasis under core hyperthermia. The farnesol realizes the function of actively enhancing physiological hemostasis under the core temperature loss condition by targeted regulation of the neutrophil extracellular trap pathway. The structure of the farnesol is as follows: 。 the invention constructs a triple technical means of 'independent of thrombin, independent of rewarming and active activation of endogenous hemostasis' through an innovative mechanism of inducing NETs by farnesol, and accurately solves the technical problems of low efficiency, slow response and high cost of the prior art under the condition of core temperature loss. The proposal fills the technical blank of enhancing physiological hemostasis by utilizing NETs, and provides a new strategy of rapidness, safety and economy for hemostasis in the temperature-losing environment. Further, the drug takes the farnesol as an active ingredient and is assisted by a pharmaceutically acceptable carrier. Further, the carrier is a random copolymer formed by copolymerizing acrylic acid-2-phenoxyethyl ester, butyl acrylate and acrylic acid. Wherein the molar ratio of the acrylic acid-2-phenoxyethyl ester, the butyl acrylate and the acrylic acid is 5-7:2-4:1. Still further, the molar ratio of 2-phenoxyethyl acrylate, butyl acrylate, and acrylic acid was 9:6:1. Acrylic acid-2-phenoxyethyl ester (CAS number: 48145-04-6), butyl acrylate (CAS number: 141-32-2), and acrylic acid (CAS number: 79-10-7) are all monomers. Further, the farnesol accounts for 0.06% -0.1% of the total mass of the medicine. Further, the medicament is used in combination with physical rewarming means or other hemostatic medicaments. Further, the core temperature loss condition refers to the body temperature being less than or equal to 35 ℃. Further, the core hypothermia condition is caused by traumatic blood loss, environmental exposure, and/or surgical anesthesia induction. Further, the rapid hemostasis means that a 50% or more reduction in bleeding is achieved within 5 minutes after administration. Compared with the prior art, the invention has the following beneficial effects: In order to explore the potential and applic